The original rationale for using this drug to target Grp78, hsc70, and mortalin is supported by proteomic analysis demonstrating that SHetA2 alters Grp78, hsc70, and their client proteins, and also disrupts mortalin/client protein complexes in endometrial cancer cells. The gene discussed is HSPA5; the disease is endometrial cancer.